First Time Loading...

Mayne Pharma Group Ltd
ASX:MYX

Watchlist Manager
Mayne Pharma Group Ltd Logo
Mayne Pharma Group Ltd
ASX:MYX
Watchlist
Price: 6.93 AUD -2.39% Market Closed
Updated: Apr 27, 2024

Mayne Pharma Group Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mayne Pharma Group Ltd
Operating Income Peer Comparison

Comparables:
RCE
NEU
BOT
PBP
C
CU6

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Mayne Pharma Group Ltd
ASX:MYX
Operating Income
-AU$165.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Recce Pharmaceuticals Ltd
ASX:RCE
Operating Income
-AU$10.9m
CAGR 3-Years
6%
CAGR 5-Years
-46%
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Operating Income
AU$204.9m
CAGR 3-Years
N/A
CAGR 5-Years
102%
CAGR 10-Years
N/A
Botanix Pharmaceuticals Ltd
ASX:BOT
Operating Income
-AU$18.3m
CAGR 3-Years
-5%
CAGR 5-Years
-1%
CAGR 10-Years
-28%
Probiotec Ltd
ASX:PBP
Operating Income
AU$20m
CAGR 3-Years
31%
CAGR 5-Years
24%
CAGR 10-Years
30%
C
Clarity Pharmaceuticals Ltd
ASX:CU6
Operating Income
-AU$26.4m
CAGR 3-Years
-56%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Mayne Pharma Group Ltd's Operating Income?
Operating Income
-165.5m AUD

Based on the financial report for Jun 30, 2023, Mayne Pharma Group Ltd's Operating Income amounts to -165.5m AUD.

What is Mayne Pharma Group Ltd's Operating Income growth rate?
Operating Income CAGR 1Y
-196%

Over the last year, the Operating Income growth was -196%.